Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma

We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Reardon, David A., Desjardins, Annick, Vredenburgh, James J., Sathornsumetee, Sith, Rich, Jeremy N., Quinn, Jennifer A., Lagattuta, Theodore F., Egorin, Merrill J., Gururangan, Sridharan, McLendon, Roger, Herndon, James E., Friedman, Allan H., Salvado, August J., Friedman, Henry S.
Formato: Artigo
Lenguaje:Inglês
Publicado: Duke University Press 2008
Materias:
Clinical Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2563055/
https://ncbi.nlm.nih.gov/pubmed/18359865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-003
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares